159996-13-1

Basic information

• Product Name: 2-(Chloromethyl)-4-ethoxypyridine
• Synonyms: 2-(Chloromethyl)-4-ethoxypyridine;2-(chloroMethyl)-4-ethoxypyridine hydrochloride
• CAS NO: 159996-13-1
• Molecular Formula: C₈H₁₀ClNO
• Molecular Weight: 171.62
• Mol File: 159996-13-1.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 256 °C at 760 mmHg
• Flash Point: 108.6 °C
• Appearance: /
• Density: 1.137
• Vapor Pressure: 0.0253mmHg at 25°C
• Refractive Index: 1.514
• PKA: 5.02±0.20(Predicted)
• CAS DataBase Reference: 2-(Chloromethyl)-4-ethoxypyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(Chloromethyl)-4-ethoxypyridine(159996-13-1)
• EPA Substance Registry System: 2-(Chloromethyl)-4-ethoxypyridine(159996-13-1)

Safety Data

• Hazardous Substances Data: 159996-13-1(Hazardous Substances Data)

Usage

General Description

2-(Chloromethyl)-4-ethoxypyridine is a chemical compound with the molecular formula C8H10ClNO. It is a pyridine derivative with a chloromethyl group and an ethoxy group attached to the 2 and 4 positions, respectively. 2-(Chloromethyl)-4-ethoxypyridine is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has also been studied for its potential biological activities, including its potential use as a building block in the development of new drugs. Its chemical properties and structure make it a versatile molecule for various applications in the field of organic chemistry.

InChI:InChI=1/C8H10ClNO/c1-2-11-8-3-4-10-7(5-8)6-9/h3-5H,2,6H2,1H3

Upstream product

• 26883-31-8 4-ethoxy-2-methyl-pyridine-1-oxide 
• 19677-69-1 (4-ethoxypyridin-2-yl)methanol 

Downstream Products

• 1126366-52-6 4-[(4-ethoxypyridin-2-yl)methoxy]-N-[2-methyl-5-(1-methyl-1H-imidazol-2-yl)phenyl]benzamide 

Relevant articles and documents

2--1H-thienoimidazoles. A Novel Class of Gastric H+/K+-ATPase Inhibitors

2-thienoimidazoles were synthesized and investigated as potential inhibitors of gastric H+/K+-ATPase.The isomers of the two possible thienoimidazole series were found to be potent inhibitors of gastric acid secretion in vitro and in vivo.Structure-activity relationships indicate that especially lipophilic alkoxy, benzyloxy, and phenoxy substituents with additional electron-demanding properties in the 4-position of the pyridine moiety combined with an unsubstituted thienoimidazole lead to highly active compounds with a favorable chemical stability.Various substitution patterns in the thienoimidazole moiety result in lower biological activity.The heptafluorobutyloxy derivative saviprazole (HOE 731, 5d) was selected for further development and is currently undergoing clinical evaluation.Comprehensive pharmacological studies indicate a pharmacodynamic profile different to omeprazole, the first H+/K+-ATPase blocker introduced on the market.